The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | New agents under investigation in sickle cell disease
The therapeutic landscape of sickle cell disease (SCD) has expanded rapidly in recent years, with several novel approvals and numerous further agents under continued investigation. Abdullah Kutlar, MD, Augusta University, Augusta, GA, discusses the range of promising approaches currently being tested in early phase clinical trials. Fetal hemoglobin (HbF) induction strategies are a major area of investigation, with histone deacetylase (HDAC) inhibitor panobinostat and immunomodulatory agent pomalidomide both showing encouraging effects in Phase I investigations. Aside from pharmacologic HbF-induction, pyruvate kinase activators are another avenue of interest. Prof. Kutlar explains how these agents may produce beneficial results in SCD. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
